NovaBridge Biosciences
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $-292.3M | $163.4M |
| FY2020 | — | $862.4M | $729.3M |
| FY2021 | — | $715.1M | $552.9M |
| FY2022 | — | $417.8M | $342.9M |
| FY2023 | — | $242.6M | $291.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $-292.3M | $163.4M |
| FY2020 | — | $862.4M | $729.3M |
| FY2021 | — | $715.1M | $552.9M |
| FY2022 | — | $417.8M | $342.9M |
| FY2023 | — | $242.6M | $291.5M |